Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
−Removed: During 2019, our Common Stock, par value $0.0001 per share, was traded on the Nasdaq Capital Market under the symbol “BIOS”.
+Added: Prior to February 3, 2020, our Common Stock, par value $0.0001 per share, was traded on the Nasdaq Capital Market under the symbol “BIOS”.
On February 3, 2020, we changed our symbol to “OPCH” and began trading on the Nasdaq Global Select Market.
10 unchanged sentences
Years Ended December 31,
+Added: 2015 2016 2017 2018 2019 2020
Option Care Health, Inc.
+Added: $ 100.00 $ 59.43 $ 166.29 $ 204.00 $ 213.14 $ 223.43
Nasdaq Composite Index $ 100.00 $ 107.50 $ 137.86 $ 132.51 $ 179.19 $ 257.38
3 unchanged sentences
The selected consolidated financial data presented below should be read in conjunction with, and is qualified in its entirety by reference to, Management’s Discussion and Analysis of Financial Condition and Results of Operations and our consolidated financial statements and the Notes thereto appearing elsewhere in this Annual Report.
−Removed: The selected consolidated financial data for the years ended December 31, 2019 and 2018 reflect the adoption of ASU 2014-09, Revenue from Contracts with Customers (“ASC 606”) and the selected financial data for the year ended December 31, 2019 reflects the adoption of ASU 2016-02, Leases (“ASC 842”).
−Removed: Further discussion on the impacts of ASC 606 can be found in Note 4, Revenue , and further discussion on the impacts of ASC 842 can be found in Note 8, Leases , within the Consolidated Financial Statements included in Item 8 of this report.
+Added: The selected consolidated financial data for the years ended December 31, 2020, 2019 and 2018 reflect the adoption of ASU 2014-09, Revenue from Contracts with Customers (“ASC 606”) and the selected financial data for the year ended December 31, 2020 and 2019 reflect the adoption of ASU 2016-02, Leases (“ASC 842”).
+Added: See Note 2, Summary of Significant Accounting Policies within the consolidated financial statements included in Item 8 of this report for further discussion on our accounting policies related to revenue and leases.
The below periods include the results of operations from BioScrip, Inc.
from the August 6, 2019 Merger Date onward.
−Removed: Prior to April 7, 2015, Option Care (the “Successor”) was a wholly owned subsidiary of Walgreen Co.
−Removed: operating under the name Walgreens Infusion Services, Inc.
−Removed: ( the Predecessor”).
−Removed: The Consolidated Statements of Comprehensive Income (Loss) presented below include the Predecessor’s results of operations for the period from January 1, 2015 through April 6, 2015 and are demarcated by a black line.
+Added: 2020 2019 2018 2017 2016
(in thousands)
5 unchanged sentences
(1) Working capital consists of total current assets less total current liabilities.
−Removed: (2) Working capital and total assets for the year ended December 31, 2019 reflect the adoption of ASU 2016-02, Leases , and are, therefore, not comparable to prior periods.
−Removed: For a full discussion on the impacts of the adoption see Note 8.
−Removed: Leases , included in Item 8 of this report.
−Removed: Periods Ended
+Added: (2) Working capital and total assets for the year ended December 31, 2020 and 2019 reflect the adoption of ASU 2016-02, Leases , and are, therefore, not comparable to prior periods.
+Added: See Note 2, Summary of Significant Accounting Policies included in Item 8 of this report for further discussion on our accounting policies related to leases.
Year Ended December 31,
−Removed: April 7, 2015 -
−Removed: December 31, 2015
−Removed: January 1, 2015 -
−Removed: April 6, 2015
+Added: 2018 2017 2016
(in thousands)
3 unchanged sentences
Operating income (loss) 110,755 (319) 38,269 27,279 52,448
−Removed: Net income (loss)
−Removed: Net comprehensive income (loss)
−Removed: Net income (loss) per share, basic and diluted (3)
+Added: Net (loss) income (8,076) (75,920) (6,115) 3,878 3,910
+Added: Net comprehensive (loss) income (12,053) (83,959) (5,341) 3,936 3,910
+Added: Net (loss) earnings per share, basic and diluted (0.04) (0.49) (0.04) 0.03 0.03
Weighted average common shares outstanding, basic and diluted 180,971 156,280 142,614 142,614 142,614
−Removed: (1) 2019 includes the results of operations of BioScrip from August 6, 2019 onward and are, therefore, not comparable to prior periods.
+Added: (1) 2020 and 2019 include the results of operations of BioScrip from August 6, 2019 onward and are, therefore, not comparable to prior periods.
(2) Net revenue and gross profit for the years ended December 31, 2020, 2019 and 2018 reflect the adoption of ASU 2014-09, Revenue from Contracts with Customers , and are, therefore, not comparable to prior periods.
−Removed: For a full discussion on the impacts of the adoption see Note 4, Revenue , included in Item 8 of this report.
−Removed: (3) Predecessor period represents the period prior to the acquisition of Walgreens Infusion Services from Walgreen Co., and therefore no shares of common stock were outstanding.
−Removed: As a result, there is no net income (loss) per share or weighted average common shares outstanding information available for this period.
+Added: See Note 2, Summary of Significant Accounting Policies included in Item 8 of this report for further discussion on our accounting policies related to revenue.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.